Targeted therapies in malignant pleural mesothelioma
IGF system in cancer
Synergistic tumor growth-inhibitory effect of the prostate-specific antigen-activated fusion peptide BSD352 for prostate cancer therapy
Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity
Effect of microtubule-targeting drugs on cell–cell and cell–matrix junctions in tumor epithelial cells
Sphingosine kinase 1 is a relevant molecular target in gastric cancer
Additive effects of trastuzumab and genistein on human breast cancer cells
In-vitro/in-vivo studies of the biodegradable poly-(d,l-lactide-co-glycolide) microspheres of a novel luteinizing hormone-releasing hormone antagonist for prostate cancer treatment
High concentrations of dichloroacetate have minor effects on the vitality of the mammalian nerve fibers
A retrospective comparative study of epirubicin–lipiodol emulsion and cisplatin–lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma
Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer
Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers
Response to degarelix after resistance to luteinizing hormone–releasing hormone agonist therapy for metastatic prostate cancer
3,3′-Diindolylmethane negatively regulates Cdc25A and induces a G2/M arrest by modulation of microRNA 21 in human breast cancer cells